Your institution may have access to this item. Find your institution then sign in to continue.
Title
First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma.
Authors
B. Melichar; P. Koralewski; A. Ravaud; A. Pluzanska; S. Bracarda; C. Szczylik; C. Chevreau; M. Filipek; R. Delva; E. Sevin; S. Négrier; J. McKendrick; A. Santoro; P. Pisa; B. Escudier